在研机构 |
最高研发阶段临床3期 |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C17H14O4S |
InChIKeyRZJQGNCSTQAWON-UHFFFAOYSA-N |
CAS号162011-90-7 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
牙痛 | 临床2期 | - | 2002-05-01 | |
术后疼痛 | 临床2期 | - | 2002-02-01 | |
腺瘤 | 临床2期 | - | 1999-12-23 | |
结直肠癌 | 临床2期 | - | 1999-12-23 |
临床3期 | - | (選窪醖願憲廠淵遞蓋遞): HR = 0.97 (95% CI, 0.81 ~ 1.16) 更多 | 不佳 | 2010-10-20 | |||
Placebo | |||||||
N/A | 内皮功能障碍 nitric oxide | - | 範鬱衊醖夢衊齋餘觸鹽(鹹膚鹹齋顧鹹網製壓齋) = 鬱襯膚壓簾憲窪廠醖鏇 遞顧膚淵鑰窪淵蓋網鬱 (糧積艱鹹繭鏇醖選襯衊, .7) | 积极 | 2010-06-01 | ||
範鬱衊醖夢衊齋餘觸鹽(鹹膚鹹齋顧鹹網製壓齋) = 觸蓋構淵鑰網顧艱鏇鹽 遞顧膚淵鑰窪淵蓋網鬱 (糧積艱鹹繭鏇醖選襯衊, .3) | |||||||
临床3期 | 2,587 | 夢鬱網製簾壓簾齋鹽遞(鹹膚選願選構夢構觸襯): hazard ratio = 1.79 (95% CI, 1.17 ~ 2.73), P-Value = 0.006 | 不佳 | 2008-11-15 | |||
Placebo | |||||||
临床3期 | - | (製獵夢構窪鬱醖觸窪構): HR = 0.91 (95% CI, 0.78 ~ 1.07), P-Value = 0.25 更多 | 积极 | 2008-05-20 | |||
Placebo | |||||||
N/A | 4,741 | 夢蓋醖築選艱鏇範觸艱(鹽顧窪願憲製鏇艱蓋膚) = There were no cases of congestive heart failure 壓淵糧構積繭遞製夢構 (願憲簾蓋構蓋襯醖積衊 ) 更多 | 积极 | 2007-09-01 | |||
Placebo | |||||||
临床3期 | 晚期非小细胞肺癌 一线 | 400 | Gemcitabine 1200 mg/m(2) + Cisplatin 80 mg/m(2) | (鑰憲繭憲壓積蓋網簾襯) = 遞鑰鑰獵築獵淵鏇醖顧 蓋蓋獵構齋觸蓋窪願齋 (窪鬱憲齋蓋餘顧觸簾醖 ) | 不佳 | 2007-06-01 | |
Gemcitabine 1200 mg/m(2) + Cisplatin 80 mg/m(2) + Rofecoxib 50 mg/day | (鑰憲繭憲壓積蓋網簾襯) = 遞淵廠築艱選鹽鹽網鬱 蓋蓋獵構齋觸蓋窪願齋 (窪鬱憲齋蓋餘顧觸簾醖 ) | ||||||
N/A | 膝关节炎 一线 | 403 | (衊廠窪窪鏇襯鹽淵選鑰) = Most commonly reported drug-related adverse events were diarrhea, nausea, pain, dyspepsia, and headache 鹽壓選範鏇鑰膚製艱膚 (醖醖夢襯夢鑰餘壓廠鑰 ) 更多 | - | 2006-06-21 | ||
临床3期 | 非小细胞肺癌 一线 | 400 | (餘獵網醖膚簾衊膚鹹糧) = 網遞繭鏇顧遞艱選築蓋 膚糧鹽艱鏇壓襯鏇獵簾 (遞膚構繭衊餘遞窪願獵 ) 更多 | 不佳 | 2006-06-20 | ||
N/A | - | (壓構構鬱顧鏇鑰選獵壓) = 選鹹襯蓋積觸夢鹽繭餘 積範糧鹹鏇積範鑰蓋顧 (衊醖夢鬱廠構廠鬱築壓, **) | 积极 | 2004-06-09 | |||
(壓構構鬱顧鏇鑰選獵壓) = 蓋憲顧鑰餘壓廠鏇構願 積範糧鹹鏇積範鑰蓋顧 (衊醖夢鬱廠構廠鬱築壓, **) | |||||||
N/A | - | 艱憲願廠鹹鏇齋構網鹹(築網蓋鬱鏇積觸製範遞) = many cases of gastrointestinal adverse events considering both the total number of adverse events (1,782 to 2,730) and the number of serious adverse events (17 to 90), as well as possible myocardial infarction episodes (5 to 29), would be avoided 壓繭夢簾觸選鏇遞壓艱 (選齋構襯窪遞簾齋餘製 ) 更多 | 积极 | 2004-06-09 | |||